The effect of lodoxamide ethyl [diethyl N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate] on in vivo anaphylactic reactions.
Orally administered iodoxamide ethyl (U-42,718) inhibited anaphylactic reactions in a dose-related manner in the following test animals: (1) in the rat PCA reaction, excellent activity (75% inhibition at 0.1 mg/kg) was seen with a duration of activity of 30 min, (2) In the ascaris-sensitive primate (45% inhibition at 1.0 mg/kg) in lung parameters related to increased resistance and decreased compliance which persisted for up to 3 h, and (3) 50 mg/kg protected guinea pigs, sensitized to egg albumin, from lung function changes. Activity in these animal systems indicates that this orally active drug may hold promise in clinical asthma.
D000336:Aerosols; D000596:Amino Acids / Q000494:pharmacology*; D000707:Anaphylaxis / Q000503:physiopathology*; D000818:Animals; D001200:Ascaris / Q000276:immunology; D005260:Female; D006168:Guinea Pigs; D000882:Haplorhini; D008253:Macaca mulatta; D008297:Male; D010047:Ovalbumin / Q000276:immunology; D010072:Oxamic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects*; D051381:Rats; D012119:Respiration / Q000187:drug effects; D013990:Tidal Volume
D000336:Aerosols; D000596:Amino Acids; D010047:Ovalbumin; D010072:Oxamic Acid; C021702:lodoxamide ethyl